Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.

Conversely, refractoriness or relapse to the latest prior therapy exerted significantly adverse effect on PFS and DOR (1-year PFS: 100.0% vs 41.7%, p=0.02, 1-year DOR: 100.0% vs 50%, p=0.03, figure 2A,B ), which was also revealed as the marginally significant adverse factor in terms of OS (1-year OS: 100.0% vs 65.5%, p=0.05, figure 2C ).

also in 26,082 other papers